A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors

Pfizer

Status and phase: Terminated; Phase 1

Conditions: Breast Cancer; Neoplasms

Treatments: Drug: PF-06650808

Study type: Interventional

Funder types: Industry

Identifiers

NCT02129205

B7501001

Details and patient eligibility

About

To assess the safety and tolerability at increasing dose levels of PF-06650808 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Enrollment: 40 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of advanced/metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available
• Previously treated metastatic triple negative breast cancer that expresses Notch3 with at least one measurable lesion
• Adequate bone marrow, renal and liver function

Exclusion criteria

• Major surgery, radiation therapy or systemic anti-cancer therapy within 4 weeks of starting study treatment
• Patients with known symptomatic brain metastases requiring steroids
• Prior treatment with a compound of the same mechanism

Trial design

40 participants in 1 patient group

PF-06650808

Experimental group

Treatment:

Drug: PF-06650808

Drug: PF-06650808